Dutch dope busts price of minty ganja gum

AXIM Biotechnologies, a small, Manhattan-based company with ties to the Netherlands, says it has a trump card in its quest to develop a cannabis-based chewing gum to ease the symptoms of multiple sclerosis.

The company says it will be able to price its gum cheaper than a major competitor after securing a "significant" discount on cannabis made available by the Dutch government.

To be sure, AXIM has a long way to go before its Medchew Rx gum - still in development - will be a viable alternative to an under-the-tongue spray developed by GW Pharmaceuticals.

That spray, Sativex, is already approved in 27 countries - though not in the US, where cannabis remains prohibited under federal law.

Provided treatment is regulated, cannabis could be therapeutic for MS patients, said Paul Wright, chairman of neurology at North Shore University Hospital in Manhasset, New York.

"I do believe that there's a role...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.